The Weill Cornell Medicine Comprehensive Thalassemia Center staff members are committed to the safety and well-being of our patients. For more information about COVID-19, here are links to other sources: the Weill Cornell COVID-19 patient guide, the Centers for Disease Control (CDC) website, the NYC Department of Health website, and the Cooley's Anemia Foundation website.
These sources provide up-to-date information on signs and symptoms, precautions to take, when to quarantine and other important tips. If you have developed a fever, cough, shortness of breath or other respiratory symptoms, please call your provider right away.
As one of the longest-standing thalassemia care centers in the country, we possess extensive experience and treatment expertise. The Weill Cornell Medicine New York Comprehensive Thalassemia Center is trusted to provide up-to-date guidelines as well as support for hematologists and primary care providers. We also have a rich history of participating in and conducting clinical trials, resulting in major care advancements in care and outcome improvements through a reduction in morbidity.
Guidelines
Guidelines developed at the New York Comprehensive Thalassemia Center, based on review of available literature and our own experience, include:
- Guidelines for Transfusion-Dependent Thalassemia (TDT) Transfusion Therapy
- Guidelines for Comprehensive Thalassemia Monitoring
- Guidelines for Thalassemia Chelation (Transfusion-Dependent and Non-Transfusion-Dependent Patients)
- Guidelines for Thalassemia Patient Pregnancy Management
Open Clinical Trials
View and participate in ongoing clinical trials at the New York Comprehensive Thalassemia Center.